The Immune Thrombocytopenia market is projected to surpass a valuation of USD 2,300 Mn at 5.78% CAGR during the forecast period. Rising prevalence of immune thrombocytopenia (ITP) worldwide has fueled the demand for ITP therapeutics. Increased government effort to improve healthcare infrastructure in countries such as India, China and Brazil has reflected favorably on the global ITP market. In addition, increased focus on development of novel drugs and therapeutics is also having a positive impact on the market. Autoimmune diseases, chronic infections, medications, pregnancy, and certain cancers are common secondary triggers of ITP.
Immune Thrombocytopenia Market Synopsis:
The MRFR report includes a thorough assessment of the global immune thrombocytopenia (ITP) market along with a five-year (2018-2023) revenue forecast. The report includes a discussion on several key market elements. The scope of the discussion also covers different ITP treatments that are currently available such as intravenous immunoglobulins, thrombopoietin receptor agonists and corticosteroids among other. It also covers revenue analysis of major end-users of immune thrombocytopenia, which covers hospitals and clinics, specialty centers, and research and academic institutes. A detail analysis of the various sub-markets across key region of the world is also available in the report.
Historical market trends, market dynamics, forecast, market value by region as well as by segmentation, country-level analysis for each market segment, key player’s market share analysis and market factor analysis which covers supply chain and Porter’s five forces analysis of the market
Immune Thrombocytopenia Market Key Players:
CSL Limited, Amgen Inc., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., Rigel Pharmaceuticals, Inc., Shionogi Inc., Dova Pharmaceuticals, Novartis AG, Jiangsu Hengrui Pharmaceutical Co., Ltd., Shire and Ligand Pharmaceuticals, Inc.
For the scope of the research, MRFR’s report offers a comprehensive segmental analysis of the Immune Thrombocytopenia market
The research methodology envelops the range and depth of Immune Thrombocytopenia market and industries that ensures the best outlooks are presented. The methodology successfully combines primary and secondary research methods to present exclusive and pertinent content that can aid in well-versed decision making. The different advances in markets are uniquely included in the reports by employing top-down and bottom-up approaches. Insightful data, advantageous scenarios, and outline of the emerging markets make for a complete and astute guide into the beat of the market. Also, the consistency levels of our reports offer our users adept intelligence that can shape the base of strategies they devise to gain the preferred market portions and hold & enhance their current customer base in several geographies.
Frequently Asked Questions (FAQ) :
Immune thrombocytopenia (ITP) market is projected to grow at a 5.78% CAGR during the forecast period.
Immune thrombocytopenia (ITP) market is predicted to touch USD 2,300 million during the forecast period.
The Americas is expected to lead the immune thrombocytopenia (ITP) market.
Rising prevalence of ITP and focus on developing new drugs are the key factors driving the immune thrombocytopenia (ITP) market.
Risk of side effects may limit the immune thrombocytopenia (ITP) market.
Immune Thrombocytopenia (ITP) Market: Company Landscape:
Numerous players are operating in the Global Immune Thrombocytopenia market. Some of the big players have captured a significant share in the global immune thrombocytopenia market, taking advantage of their strong position and presence in the number of countries across the world. The top players in the global immune thrombocytopenia market are Novartis, Shire, and, Amgen, which hold a significant market share.
Novartis accounted for the major market share in 2017. The company has a diverse product portfolio in therapeutic areas including oncology, cardiology, ophthalmology, immunology, and dermatology. The market share is due to the company’s product Promacta which is used for treating chronic immune thrombocytopenia (ITP). The company is focused on launching the product in global markets. For instance, in April 2016, the company received the European Commission approval for Promacta/Revolade for the treatment of ITP. Additionally, the company has a distribution network globally and is focusing on strengthening its presence in untapped regions.
Shire is a prominent player in the Global Immune Thrombocytopenia market. Shire has a strong product portfolio in various therapeutic areas. The company has a strategy of entering in strategic collaborations to strengthen its market presence. For instance, in June 2016, Shire entered into a strategic partnership with Baxalta Incorporated (US). With this collaboration, the company strengthened the product portfolio of rare diseases. Additionally, the company has a strong distribution network in more than 100 countries with a strong presence in countries such as Ireland and the US.
Amgen is a renowned company in the market. The company focuses on research, development, and manufacture of innovative human therapeutic products. The company has a strategy of developing innovative medicines to meet unmet medical needs. The company’s products are available to patients in about 100 countries worldwide with strong market penetration in the US.
Apart from these companies, there are several other players in the market. The other players include CSL Limited, F. Hoffman Roche, Jiangsu Hengrui Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Rigel Pharmaceuticals, Inc., and Shionogi, Inc. Majority of these players have ITP treatment drugs in the pipeline.